Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer

STATUS

Recruiting
End date

Dec 21, 2025
participants needed

100
sponsor

Pia Osterlund

Send

Updated on 21 January 2021

See if I qualify

serum bilirubin level

metastasis

neutrophil count

bevacizumab

adjuvant chemotherapy

proteinuria

xelox regimen

xeliri

Summary

Open-label, single-arm, phase II study of bevacizumab (AvastinTM) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer.
- Primary objective: PFS, To assess overall resectability in patients with metastatic colorectal cancer, postoperative morbidity and outcomes after resection.
- Secondary objectives: To assess response rates according to RECIST criteria, failure free survival (TTF) and overall survival (OS), Quality of life according to 15D questionnaire, To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria, Biomarker evaluation to measure plasma biomarkers, tumour blocks and DNA polymorphisms that may predict drug effects, safety, resectability and clinical behaviour of the tumour

Details

Condition	Metastatic Colorectal Cancer
Treatment	Bevacizumab plus alternating Xelox/Xeliri
Clinical Study Identifier	NCT01531595
Sponsor	Pia Osterlund
Last Modified on	21 January 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients with histologically confirmed diagnosis of CRC, chemotherapy nave for metastatic disease (prior adjuvant chemotherapy more than 6 months previously for CRC allowed), who are scheduled to start first line chemotherapy for metastatic disease
	Age > 18
	Measurable or evaluable metastatic disease
	Performance status ECOG performance status 0-2
	Life expectancy greater than 3 months
	Normal Thrombocytes, neutrophils, Aspartate amino transferase/Alanine amino transferase, Alkaline phosphatase, Serum bilirubin, Serum Creatinine, Urine dipstick of proteinuria
	Women of childbearing potential must have a negative serum pregnancy test done prior to the administration of bevacizumab. Patient and their partner should have adequate contraception up to at least 6 months after last treatment completion or the last drug dose, whatever happens first
	Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee [IEC]) will be obtained prior to any study specific screening procedures
	Patient must be able to comply with the protocol
Exclusion Criteria
	Prior treatment with first-line chemotherapy for metastatic CRC
	Adjuvant treatment within 6 months
	Major surgical procedure (placing of central venous access device and liver biopsy etc are considered minor procedure), open biopsy or significant traumatic injury within 28 days prior to Day 0 (Patients must have recovered from any major surgery)
	Near future planned radiotherapy for underlying disease (prior completed radiotherapy treatment allowed)
	Clinical or radiological evidence of CNS metastases
	Past or current history within the last 2 years of malignancies except for the indication under this study and curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix
	Serious non-healing wound or ulcer
	Evidence of bleeding diathesis or coagulopathy
	Uncontrolled hypertension
	Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents ( 6 months), myocardial infarction ( 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
	Treatment with any investigational drug within 30 days prior to enrolment
	Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the treatment or patient at high risk from treatment complications
	Chronic daily intake of aspirin (> 325 mg/day) or clopidogren (> 75 mg/day)
	Pregnancy (positive serum pregnancy test) and lactation
	Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

serum bilirubin level

metastasis

neutrophil count

bevacizumab

adjuvant chemotherapy

proteinuria

xelox regimen

xeliri

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer